Development of novel therapies for Huntington's disease: hope and challenge.

about

Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.Childhood-onset (Juvenile) Huntington's disease: A rare case report.

P2860

Q36606399-DC7E4E74-8F8E-4471-A080-D34B3E29DD95 Q43211838-59FAB475-562C-47F5-8BDE-B36A4DE32FA9

P2860

Development of novel therapies for Huntington's disease: hope and challenge.

Item

http://www.wikidata.org/entity/Q36016932

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Development of novel therapies for Huntington's disease: hope and challenge.

@ast

Development of novel therapies for Huntington's disease: hope and challenge.

@en

type

Item

label

Development of novel therapies for Huntington's disease: hope and challenge.

@ast

Development of novel therapies for Huntington's disease: hope and challenge.

@en

prefLabel

Development of novel therapies for Huntington's disease: hope and challenge.

@ast

Development of novel therapies for Huntington's disease: hope and challenge.

@en

P1476

Development of novel therapies for Huntington's disease: hope and challenge.

@en

P2093

Jin Wang

http://www.w3.org/2001/XMLSchema#string

Zhen-Lun Gu

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of Huntington disease protein with transcriptional activator Sp1

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

A cell-based screen for drugs to treat Huntington's disease.

P2888

j.1745-7254.2005.00520.x

P304

129-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1745-7254.2005.00520.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zheng-Hong Qin

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8067460

http://www.w3.org/2001/XMLSchema#string

P6179

1044080588

http://www.w3.org/2001/XMLSchema#string

P698

15663888

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

Development of novel therapies for Huntington's disease: hope and challenge.

about

P2860

P2860

Development of novel therapies for Huntington's disease: hope and challenge.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P921